MIRM Shares Slide on Volixibat Regulatory Delay Despite Robust Q2 Results

Mirum reported robust Q2 2026 net sales of $176.2 million and hiked guidance, yet MIRM stock fell sharply after the FDA asked for an additional Phase 3 study for its PSC drug volixibat.